Shanghai Ming Ju Biotechnology Co., Ltd. Report issue

Government Phase 2

Organization Overview

First Clinical Trial
2019
NCT04089215
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Shanghai Ming Ju Biotechnology Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

cd19 car-t cells (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1